Standard Rituximab Dose May Be Inadequate to Maintain B-Cell Depletion in ANCA-Associated Vasculitis
>
>
Standard Rituximab Dose May Be Inadequate to Maintain B-Cell Depletion in ANCA-Associated Vasculitis

Standard Rituximab Dose May Be Inadequate to Maintain B-Cell Depletion in ANCA-Associated Vasculitis

•The standard rituximab maintenance dosing of 500 mg every 6 months may be insufficient to maintain B-cell depletion in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

The percentage of patients with undetectable B cells was 100% in the high intensity group compared with 69% and 60% in the low and standard groups, respectively (P =.03). ANCA negativity did not appear to be significantly associated with dose regimen.

Standard RTX maintenance dosing intensity of 500 mg every 6 months may be inadequate to maintain B cell depletion in a significant number of patients. A target RTX dose intensity of greater than 3.3 mg [per day] is required to maintain B-cell depletion

Read More: Springer J, Funk R. Pharmacological response of rituximab based on dose intensity in maintenance therapy of ANCA-associated vasculitis. Presented at: ACR Convergence 2021; November 3-10, 2021. Abstract 0416.

Share on

There are no comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Start typing and press Enter to search

Shopping Cart